Showing 2201-2210 of 2652 results for "".
- Regeneron's Antibody Cocktail Offers Long-Term Protection Against COVID-19https://modernod.com/news/regenerons-antibody-cocktail-offers-long-term-protection-against-covid-19/2480418/Regeneron Pharmaceuticals said Monday that a single dose of the antibody cocktail REGEN-COV (casirivimab and imdevimab) reduced the risk of contracting COVID-19 by 81.6% in the two- to eight-month period after it was given. The result is in line with an
- Visus Therapeutics Appoints David Guyer, MD, as Chairman of the Board, and Names Ted Danse as Head of Business Developmenthttps://modernod.com/news/visus-therapeutics-appoints-david-guyer-md-as-chairman-of-the-board-and-names-ted-danse-as-head-of-business-development/2480395/Visus Therapeutics announced the appointment of ophthalmology and industry expert David Guyer, MD, as the chairman of the Board after serving as an advisor since the company’s inception, and life sciences veteran Ted Danse as the head of business development. “I&rs
- FDA Clears Emergency Use of Comirnaty in Children Aged 5 to 11https://modernod.com/news/fda-clears-emergency-use-of-comirnaty-in-children-aged-5-to-11/2480386/The FDA on Friday authorized emergency use of Pfizer and BioNTech's Comirnaty for the prevention of COVID-19 to include children 5 through 11 years of age. The vaccine is administered as a two-dose primary series, 21 days apart, but at a lower 10-mcg dose than that used for individuals 12 yea
- Ocular Therapeutix to Present Data at the American Academy of Ophthalmology (AAO) 2021 Virtual Annual Meetinghttps://modernod.com/news/ocular-therapeutix-to-present-data-at-the-american-academy-of-ophthalmology-aao-2021-virtual-annual-meeting/2480384/Ocular Therapeutix announced multiple scientific presentations at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting being held November 12-15, 2021. “We are happy to have a large presence at AAO this year with six poster presentations in five different indicatio
- Prevent Blindness: Senate FY2022 Appropriations Bill Doubles Funding for the CDC’s Vision and Eye Health Programhttps://modernod.com/news/prevent-blindness-senate-fy2022-appropriations-bill-doubles-funding-for-the-cdcs-vision-and-eye-health-program/2480364/This week, the Senate Appropriations Committee released its proposed legislation to fund programs under the Department of Health and Human Services in Fiscal Year (FY) 2022. "As a result of continued Prevent Blindness advocacy efforts, the Senate Appropriations legislation includes
- Quantel Medical Launches Website Dedicated to Laser Therapies for Retinal Disordershttps://modernod.com/news/quantel-medical-launches-website-dedicated-to-laser-therapies-for-retinal-disorders/2480357/Quantel Medical announced its new website, www.subliminal-laser-therapy.com, dedicated to laser therapies for retinal disorders. "Over the years, the development and introduction of new and innovative laser technologies has
- Amidst the COVID-19 Pandemic, Early Intervention Remains an Obstacle for Overall Eye Health Despite Fear of Blindnesshttps://modernod.com/news/amidst-the-covid-19-pandemic-early-intervention-remains-an-obstacle-for-overall-eye-health-despite-fear-of-blindness/2480352/Globally, most adults, 70 percent, don’t plan to get their eyes examined this year, despite acknowledging the critical importance of eye health. These new findings come from a comprehensive, large-scale Johnson & Johnson Vision Global Eye Health Survey announced in advance of World Sigh
- 2021 American Academy of Optometry & Foundation Resident Travel Fellowship Recipientshttps://modernod.com/news/2021-american-academy-of-optometry-foundation-resident-travel-fellowship-recipients/2480331/The American Academy of Optometry and its Foundation would like to congratulate the recipients of this year’s Resident Travel Fellowships. These travel fellowsh
- Adverum Presents Data Showing Gene Therapy Maintained Efficacy, Durability, Safety in Wet AMD Patientshttps://modernod.com/news/adverum-data-shows-gene-therapy-maintained-efficacy-durability-safety-in-wet-amd-patients/2480318/Adverum Biotechnologies announced new long-term data from the OPTIC clinical trial of ADVM-022 single, in-office intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration (AMD). Safety and efficacy data f
- Graybug Vision Reports Analysis of Data from the 6-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMDhttps://modernod.com/news/graybug-vision-reports-analysis-of-data-from-the-6-month-extension-study-of-the-altissimo-phase-2b-trial-in-wet-amd/2480304/Graybug Vision provided full-data analysis from the 18-month Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (AMD), Graybug’s proprietary formulation of sunitinib malate injected twice-a-year intravitreally. The ALTISSIMO trial was